Advanced search
Publication Cover
Journal of Medical Economics Volume 17, 2014 - Issue 9
Submit an article Journal homepage
1,174
Views
16
CrossRef citations to date
0
Altmetric
Neurology: Original articles

Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence

Emilie ClayCreativ-Ceutical ParisFrance
,
Amine KhemiriCreativ-Ceutical ParisFrance
,
Vladimir ZahZRx Outcomes Research Inc. Mississauga, ONCanada
,
Samuel AballéaCreativ-Ceutical ParisFrance
,
Jane RubyReckitt Benckiser Pharmaceuticals, Inc. Richmond, VAUSA
&
Carl V. AscheCenter for Outcomes Research, University of Illinois College of Medicine at Peoria Peoria, ILUSACorrespondence[email protected]
Pages 626-636 | Accepted 14 May 2014, Published online: 06 Jun 2014

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Carl V. Asche, Emilie Clay, Elizaveta Kharitonova, Vladimir Zah, Jane Ruby & Samuel Aballéa. (2015) Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States. Journal of Medical Economics 18:8, pages 600-611.
Read now

Articles from other publishers (15)

Naomi van Hest, Thomas D. Brothers, Andrea Williamson & Dan Lewer. (2023) Health‐care resource use among patients who use illicit opioids in England, 2010–20: A descriptive matched cohort study. Addiction.
Crossref
Manesh GopaldasKevin WenzelAimee N. C. CampbellAli JalaliMarc FishmanJohn RotrosenEdward V. NunesSean M. Murphy. (2023) Impact of Medication-Based Treatment on Health Care Utilization Among Individuals With Opioid Use Disorder. Psychiatric Services 74:12, pages 1227-1233.
Crossref
Teodor Vikbladh, Katja Troberg, Anders Håkansson & Disa Dahlman. (2022) Healthcare utilization for somatic conditions among Swedish patients in opioid substitution treatment, with and without on-site primary healthcare. BMC Health Services Research 22:1.
Crossref
Benjamin D. Hallowell, Laura C. Chambers, Elizabeth A. Samuels, Jeffrey Bratberg, James McDonald, Adam Nitenson, Collette Onyejekwe & Francesca L. Beaudoin. (2022) Sociodemographic and prescribing characteristics that impact long-term retention in buprenorphine treatment for opioid use disorder among a statewide population. Drug and Alcohol Dependence 241, pages 109680.
Crossref
Megann Mitchell. (2021) Medicolegal Considerations in the Management of Opioid Use Disorder With Buprenorphine in the Correctional Setting. Journal of Correctional Health Care 27:3, pages 210-214.
Crossref
Lia N. Pizzicato, Jeffrey K. Hom, Monica Sun, Caroline C. Johnson & Kendra M. Viner. (2020) Adherence to buprenorphine: An analysis of prescription drug monitoring program data. Drug and Alcohol Dependence 216, pages 108317.
Crossref
Tami L. Mark, Jesse M. Hinde, Gary A. Zarkin, William Parish & Marianne Kluckman. (2020) Adherence to buprenorphine treatment guidelines among individuals with an opioid use disorder who have private insurance. Journal of Substance Abuse Treatment 116, pages 108062.
Crossref
Dan Lewer, Joseph Freer, Emma King, Sarah Larney, Louisa Degenhardt, Emily J. Tweed, Vivian D. Hope, Magdalena Harris, Tim Millar, Andrew Hayward, Dan Ciccarone & Katherine I. Morley. (2020) Frequency of health‐care utilization by adults who use illicit drugs: a systematic review and meta‐analysis. Addiction 115:6, pages 1011-1023.
Crossref
Audrey A. Klein & Marvin D. Seppala. (2019) Medication-assisted treatment for opioid use disorder within a 12-step based treatment center: Feasibility and initial results. Journal of Substance Abuse Treatment 104, pages 51-63.
Crossref
Marcia Reinhart, Lauren M. Scarpati, Noam Y. Kirson, Cody Patton, Nina Shak & Jennifer G. Erensen. (2018) The Economic Burden of Abuse of Prescription Opioids: A Systematic Literature Review from 2012 to 2017. Applied Health Economics and Health Policy 16:5, pages 609-632.
Crossref
Natalia Shcherbakova, Gary Tereso, Jacqueline Spain & Robert J. Roose. (2018) Treatment Persistence Among Insured Patients Newly Starting Buprenorphine/Naloxone for Opioid Use Disorder. Annals of Pharmacotherapy 52:5, pages 405-414.
Crossref
Ajay Manhapra, Ismene Petrakis & Robert Rosenheck. (2017) Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration. The American Journal on Addictions 26:6, pages 572-580.
Crossref
Sean M. Murphy & Daniel Polsky. (2016) Economic Evaluations of Opioid Use Disorder Interventions. PharmacoEconomics 34:9, pages 863-887.
Crossref
Erik W. Gunderson & Michael Sumner. (2016) Efficacy of Buprenorphine/Naloxone Rapidly Dissolving Sublingual Tablets (BNX-RDT) After Switching From BNX Sublingual Film. Journal of Addiction Medicine 10:2, pages 124-130.
Crossref
Richard J. Bodnar. (2016) Endogenous opiates and behavior: 2014. Peptides 75, pages 18-70.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.